C. Lovejoy

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

R. Burger, E. Sausville, R. Coleman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

R. Messmann, N. Gabrail, R. Naumann, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

R. Burger, E. Sausville, R. Coleman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

C. Leamon, C. Lovejoy, B. Nguyen, 2013, Pharmacogenomics and personalized medicine.